The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting proposals for contracts entitled “Development of Medical Countermeasures to Enhance Platelet Regeneration and Survival Following Radiation Exposure from a Radiological/Nuclear Incident.”
The effort seeks to advance the development of candidate medical countermeasures toward eventual Food and Drug Administration (FDA) approval or licensure to mitigate radiation-induced thrombocytopenia and thereby improve survival.
Proposals will be evaluated on the underlying data supporting the amelioration of radiation-induced thrombocytopenia and improved survival, and the comprehensiveness, soundness, adequacy and suitability of the proposed scientific approach and methodology used to support the advancement of the candidate countermeasure.
It is anticipated that 2-4 cost reimbursement, completion type contracts will be awarded for a 3-year period of performance with an estimated start date in June 2014.
Further details are available under Solicitation Number: BAA-NIAID-DAIT-NIHAI2013166. The BAA closes on July 1, 2013.
